FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K/A

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October, 2005

 

SkyePharma PLC


(Translation of registrant's name into English)

 

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England


(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______


 

For immediate release                                            18 October 2005


This announcement replaces the Notification of Shares announcement which was
released on 17th October at 12.43 under RNS number 7622S.


                         SkyePharma PLC ("the Company")
                    Notification of Major Interest in Shares



The Company was informed by Fidelity Investments on 18 October 2005 that, as a
result of an administrative oversight, the Company had been sent an incorrect
notification on 17 October 2005. The Company was informed that, as at the
beginning of 18 October 2005, the revised holding of FMR Corp and its direct and
indirect subsidiaries and Fidelity International Limited and its direct and
indirect subsidiaries, both being non-beneficial holders ("Fidelity"), amounted
to 75,523,745 ordinary shares of 10p each, representing 12.02% of the issued
share capital of the Company.



                                    - ends -

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ Douglas Parkhill

                                                                       Name: Douglas Parkhill
                                                                          Title: Company Secretary

Date:    October 18, 2005